<DOC>
	<DOCNO>NCT01718639</DOCNO>
	<brief_summary>This study randomize , placebo-controlled , single-blind , three-way crossover clinical trial evaluate safety efficacy IQP-LH-101 ( tablet form liquid form ) postprandial heartburn . The null hypothesis difference IQP-LH-101 placebo term efficacy postprandial heartburn treatment .</brief_summary>
	<brief_title>Safety Efficacy IQP-LH-101 Postprandial Heartburn</brief_title>
	<detailed_description />
	<mesh_term>Heartburn</mesh_term>
	<criteria>Postprandial heartburn ( e.g . highfat meal ) least 2 month prior study ( least 2 time week ) Not receive prescribe treatment heartburn , reflux upper gastrointestinal disorder Written inform consent prerequisite subject enrollment . Gastrointestinal bleeding within 12 month prior study Difficulty swallow ( dysphagia ) History symptom suggestive ZollingerEllison syndrome , oesophageal gastric malignancy , gastric duodenal ulcer , pernicious anaemia , Barrett 's oesophagus systemic sclerosis Participation study within last 30 day prior entry study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>